Analyzing Cost of Revenue: Pfizer Inc. and Xencor, Inc.

Analyzing Cost of Revenue: Pfizer Inc. vs. Xencor, Inc.

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. From 2014 to 2023, Pfizer Inc. and Xencor, Inc. have shown contrasting trajectories in their cost of revenue. Pfizer, a global giant, saw its costs surge by over 200% from 2014 to 2022, peaking in 2022. This reflects its expansive operations and significant R&D investments. In contrast, Xencor, a smaller biotech firm, experienced a more modest increase, with costs rising by approximately 1,270% over the same period, highlighting its growth phase and scaling efforts. Notably, Pfizer's cost of revenue in 2023 was nearly 350 times that of Xencor, underscoring the scale difference. These insights reveal the dynamic nature of the industry, where established players and emerging innovators navigate distinct financial landscapes.